ARS Pharmaceuticals, Inc. SPRY Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$197.98M-15.6% | -$171.3M-114% | -$80.04M-66.7% | -$48.02M-207% | -$15.65M-296% | ||
| $1.48M+8.6% | $1.37M+39.6% | $979K+60.8% | $609K+75.0% | $348K+341% | ||
| $24.22M+9.6% | $22.1M+7.1% | $20.62M+11.3% | $18.52M+12.1% | $16.52M+13.6% | ||
| -$175.07M-2.5% | -$170.87M-100% | -$85.38M-61.7% | -$52.8M-158% | -$20.48M-251% | ||
| $248K-26.8% | $339K-47.1% | $641K+9.8% | $584K+2.3% | $571K+1.4% | ||
| —— | —— | —— | —— | —— | ||
| $104.03M-0.5% | $104.6M-40.0% | $174.38M+132% | $75.02M+3.0% | $72.87M+0.6% | ||
| -$15.54M-63.6% | -$9.5M— | —— | —— | —— | ||
| -$175.32M-2.4% | -$171.21M-99.0% | -$86.02M-61.1% | -$53.38M-154% | -$21.06M-262% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ARS Pharmaceuticals, Inc. generate?
- ARS Pharmaceuticals, Inc. (SPRY) generated -$175.1M in operating cash flow over the trailing twelve months.
- What is ARS Pharmaceuticals, Inc.'s free cash flow?
- After $248.0K of capital expenditures, ARS Pharmaceuticals, Inc.'s free cash flow was -$175.3M over the trailing twelve months, down 732.7% year over year.
- Where does ARS Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
